Disease areas

Liver and digestive diseases

26 public biotech companies we cover are developing treatments for MASH, ulcerative colitis, Crohn's disease, cholestatic liver disease and other digestive conditions. 18 upcoming catalysts are listed below, with dates as the companies gave them.

Companies

Upcoming catalysts

Firm dates · a specific day set by the company or regulator

Next 30 days

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in November 2026

Expected in December 2026

Expected in Q4 2026

  • Q4 2026
    Lanifibranor · Phase 3 topline results (NATiV3) · Metabolic dysfunction-associated steatohepatitis (MASH)
  • Q4 2026
    IV Choline Chloride · Phase 2b/3 interim results (THRIVE-3) · Parenteral support dependence

Expected in H2 2026

Expected by end of 2026

Expected in January 2027

Expected in Q1 2027

Expected in Q2 2027

Expected in H1 2027

Expected by end of June 2027

Other disease areas